IPCA labs stock has corrected about 30 percent in recent times due to input costs pressures and return of pre-COVID expenses such as travel and promotion.
However Anubhav Sahu of moneycontrol.com believes there is merit in current valuations.
He said the company has relatively higher exposure to domestic markets wherein its top end traction is strong, domestic sales have benefited from the pick-up in acute therapies. The company also has a strong hold in pain management offerings.
The company plans to further strengthen the domestic business by expanding its business into orthopaedic and cardiovascular therapies.
Watch video for more details.
Disclaimer: The views and investment tips expressed by investment experts on CNBCTV18.com are their own and not that of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
